Chronic fatigue syndrome (Myalgic Encephalomyelitis) is a disorder that causes extreme long lasting fatigue that limits your ability to do ordinary daily activities. Symptoms may include fatigue for 6 months or more and experiencing other problems such as muscle pain, memory problems, headaches, pain in multiple joints, sleep problems, sore throat and tender lymph nodes. The cause of chronic fatigue syndrome is unknown. There is no cure for chronic fatigue syndrome so the goal of treatment is to improve symptoms. Medicines may treat pain, sleep disorders and other problems.
A new study has shown that overactive immune systems may be the trigger that gives rise to chronic fatigue syndrome (CFS). The study results were published in the latest issue of the journal Psychoneuroendocrinology.
A study led by researchers at the Center for Infection and Immunity at Columbia University's Mailman School of Public Health has identified a constellation of metabolites related to myalgic encephalomyelitis/chronic fatigue syndrome.
The National Institutes of Health has awarded a five-year $9.6 million grant to the Center for Infection and Immunity at Columbia University's Mailman School of Public Health to create the Center for Solutions for Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (CfS for ME/CFS), an inter-disciplinary, inter-institutional research group dedicated to understanding the biology of the disease in order to develop effective means to diagnose, treat and prevent it.
Scientists at the Center for Infection and Immunity at Columbia University's Mailman School of Public Health have discovered abnormal levels of specific gut bacteria related to chronic fatigue syndrome/myalgic encephalomyelitis, or ME/CFS, in patients with and without concurrent irritable bowel syndrome, or IBS.
Major improvement in the diagnosis of Chronic Fatigue Syndrome is expected following the award of $4m in funding to one of Australia’s foremost authorities on the condition.
Chronic fatigue syndrome (CFS), sometimes referred to as myalgic encephalomyelitis (ME), a mysterious, debilitating and misunderstood disease that affects an estimated 1 million Americans, will be the focus of an international conference on October 27-30, 2016.
By better understanding daily activity levels and heart rate patterns of those who suffer from Chronic Fatigue Syndrome (CFS), scientists hope to discover more about this complex illness condition.
A new finding in the cause of Chronic Fatigue Syndrome has been identified by researchers at Griffith University who say they are getting much closer to a complete understanding of this disabling condition.
New findings regarding the pathology of Chronic Fatigue Syndrome (CFS) are bringing Griffith University researchers closer to identifying the cause of this disabling illness.
In what is believed to be the biggest study of chronic fatigue syndrome (CFS) -- also known as myalgic encephalomyelitis (ME) -- in children to date, researchers at the University of Bristol (UK), have found that almost 2 per cent of 16-year-olds have CFS lasting more than six months and nearly 3 per cent have CFS lasting more than three months (the UK definition).
People suffering from Chronic Fatigue Syndrome (CFS) could experience higher levels of visual stress than those without the condition, according to new research from the University of Leicester.
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a detailed scientific review of the evidence surrounding reports of two syndromes, complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS) in young women given human papillomavirus (HPV) vaccines.
New research findings may shed new light on the potential cause of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).
Scientists at Columbia University's Mailman School of Public Health have identified a unique pattern of immune molecules in the cerebrospinal fluid of people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) that provides insights into the basis for cognitive dysfunction--frequently described by patients as "brain fog"--as well as new hope for improvements in diagnosis and treatment.
Routledge Journals is pleased to announce a new Special Issue from the Journal of Prevention & Intervention in the Community exploring topics and constructs that could help clarify uncertainties surrounding Chronic Fatigue Syndrome (CFS), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), or Myalgic Encephalomyelitis (ME) research.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome -- commonly referred to as ME/CFS -- is a legitimate, serious, and complex systemic disease that frequently and dramatically limits the activities of affected individuals, says a new report from the Institute of Medicine.
Reducing fears that exercise or activity will make symptoms worse is one of the most important factors determining the success of cognitive behaviour therapy (CBT) or graded exercise therapy (GET) in reducing fatigue and improving physical function in people with chronic fatigue syndrome (CFS), according to new analysis of data from the PACE trial, reported in The Lancet Psychiatry journal.
A new oral medication known as IMC-1, developed by Innovative Med Concepts, proved highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial.
Providing increased services for Chronic Fatigue Syndrome sufferers will be the focus of Griffith research following the award of a $1.85m grant to one of Australia’s foremost authorities on the condition.
Sufferers of Chronic Fatigue Syndrome are set to benefit with the dual launch of a specialist Griffith University clinic and smartphone app, both aimed to manage their illness and improve health outcomes.